Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 5-Mar 8:00 AM ET)
Avadel Pharmaceuticals Positioned for Growth: Buy Rating Affirmed by Analyst Marc Goodman
TipRanks (Tue, 4-Mar 10:26 PM ET)
Avadel Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
TipRanks (Tue, 4-Mar 7:20 PM ET)
Needham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)
TipRanks (Tue, 4-Mar 6:37 AM ET)
TipRanks (Tue, 4-Mar 6:21 AM ET)
Geopolitical Shifts Threaten Avadel Pharmaceuticals’ Financial Stability
TipRanks (Tue, 4-Mar 1:00 AM ET)
Avadel Pharmaceuticals Reports Strong Growth in 2024
TipRanks (Mon, 3-Mar 11:00 PM ET)
Craig-Hallum Sticks to Its Buy Rating for Avadel Pharmaceuticals (AVDL)
TipRanks (Mon, 3-Mar 9:00 AM ET)
Avadel Pharmaceuticals GAAP EPS of -$0.05 misses by $0.01, revenue of $50.41M beats by $0.38M
Seeking Alpha News (Mon, 3-Mar 7:15 AM ET)
Globe Newswire (Mon, 3-Mar 7:00 AM ET)
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Avadel Pharmaceuticals PLC - Ordinary Share trades on the NASDAQ stock market under the symbol AVDL.
As of March 5, 2025, AVDL stock price climbed to $7.76 with 353,744 million shares trading.
AVDL has a beta of 1.19, meaning it tends to be more sensitive to market movements. AVDL has a correlation of 0.05 to the broad based SPY ETF.
AVDL has a market cap of $747.06 million. This is considered a Small Cap stock.
Last quarter Avadel Pharmaceuticals PLC - Ordinary Share reported $50 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $380,000 and missed earnings estimates by -$.01.
In the last 3 years, AVDL traded as high as $19.09 and as low as $1.05.
The top ETF exchange traded funds that AVDL belongs to (by Net Assets): VTI, IWM, IWO, VTWO, VHT.
AVDL has underperformed the market in the last year with a price return of -51.9% while the SPY ETF gained +14.7%. AVDL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.1% and -9.1%, respectively, while the SPY returned -4.1% and -5.0%, respectively.
AVDL support price is $7.37 and resistance is $7.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVDL shares will trade within this expected range on the day.